You are here

A hormonal therapy for preeclampsia

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HD082698-01
Agency Tracking Number: R41HD082698
Amount: $223,676.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NICHD
Solicitation Number: HD14-032
Timeline
Solicitation Year: 2014
Award Year: 2015
Award Start Date (Proposal Award Date): 2015-01-13
Award End Date (Contract End Date): 2015-12-31
Small Business Information
3353 ALMA ST, STE 245
Palo Alto, CA 94306-3514
United States
DUNS: 078502248
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 SHEAUYU HSU
 (650) 723-7057
 teddyhsu@stanford.edu
Business Contact
 SHEAU YU HSU
Phone: (650) 799-3496
Email: relaxinangel@gmail.com
Research Institution
 WAYNE STATE UNIVERSITY
 
DETROIT, MI 48202-4050
United States

 Nonprofit college or university
Abstract

DESCRIPTION provided by applicant Preeclampsia is a pregnancy specific hypertensive disorder that can lead to multi organ failure seizure and maternal death Preeclampsia is also responsible for as many as of premature births in the United States Although better neonatal care has improved the likelihood of preterm babies surviving many face increased mortality and serious long term morbidities It is generally agreed that the best approach to prevent adverse preeclampsia associated complications is to delay premature birth Unfortunately current treatments are ineffective at delaying labor by more than a couple of days in the majority of preeclampsia patients Although the cause of preeclampsia remains to be clearly defined preeclampsia has been proposed to involve an altered balance between pro and anti angiogenic factors dysregulated immune response to the allogenic fetus incomplete trophoblast invasion and remodeling of spiral arteries or a combination of impaired oxygen supply and placental oxidative stress These defects could lead to restricted maternal fetal blood circulation and systemic endothelial dysfunction leading to high blood pressure proteinuria and fetal growth restriction Recent studies have shown that signaling of CLR RAMP receptors plays critical roles in the development of feto placental tissues and vasotone regulation during pregnancy Importantly it has been shown that blocking of CLR RAMP receptor signaling leads to preeclampsia like symptoms in pregnant animals On the other hand the activation of CLR RAMP receptors can dampen preeclampsia like symptoms in animals that have been pretreated with a nitric oxide synthase inhibitor or a CLR RAMP receptor antagonist Therefore pharmacological activation of CLR RAMP receptors could be a promising approach for treating hypertension proteinuria and fetal growth restriction in preeclampsia patients Our goal is to develop a hormonal therapy based on stable CLR RAMP receptor agonists that we recently developed This therapy is expected to have potent efficacy in reducing blood pressure edema proteinuria and fetal growth restriction in preeclampsia patients thereby reducing preterm birth resulting from preeclampsia Successful demonstration of the efficacy of lead compounds would validate our drug candidates and facilitate the preclinical development of these therapeutic candidates in the Phase II STTR investigation

PUBLIC HEALTH RELEVANCE Based on human hormones that play critical roles in implantation and placental development during pregnancy we have developed novel therapeutic candidates for the treatment of preeclampsia We will investigate the efficacy of the novel therapeutic candidates in normal pregnant and preeclamptic rats Successful development of this therapy has the potential to prevent preeclampsia and to reduce preterm birth resulting from preeclampsia

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government